-90%

est. 2Y upside i

HealthcareSeed

The API for Diagnostic Test Analysis (COVID-19, FLU, RSV, STD,…

Rank

#2373

Sector

HealthTech

Est. Liquidity

~6Y

Data Quality

Data: Medium

This opportunity presents moderate upside with high risk, typical for a Seed-stage company operating in a rapidly growing but highly competitive and regulated HealthTech AI market.

Last updated: February 16, 2026

Bull (15%)+400%

Scanbase achieves rapid market adoption by securing key partnerships and successfully navigating regulatory approvals, leading to a significant strategic acquisition.

Base (40%)+50%

Scanbase demonstrates steady progress in product development and customer acquisition, securing follow-on funding rounds and achieving a modest valuation increase.

Bear (45%)-90%

Scanbase struggles to differentiate its offering in a crowded market, faces insurmountable regulatory hurdles, or is outcompeted by well-funded incumbents, resulting in a substantial loss of value or failure.

Est. time to liquidity~6.0 years

Other — 1 role

View all 1 open roles at Scanbase →

Last updated: March 10, 2026

Community

Valuation Sentiment

Our model estimates -90% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.